Negative feedback regulation of the ERK1/2 MAPK pathway
暂无分享,去创建一个
[1] U. Rapp,et al. Active Ras induces heterodimerization of cRaf and BRaf. , 2001, Cancer research.
[2] F. McCormick,et al. Regulation of Epidermal Growth Factor Receptor Signaling by Phosphorylation of the Ras Exchange Factor hSOS1 (*) , 1996, The Journal of Biological Chemistry.
[3] Hiroshi Sakaue,et al. The Molecular Scaffold Kinase Suppressor of Ras 1 (KSR1) Regulates Adipogenesis , 2005, Molecular and Cellular Biology.
[4] Philippe P Roux,et al. RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MAPK activation. , 2012, The Biochemical journal.
[5] Julian Downward,et al. EGF induced SOS phosphorylation in PC12 cells involves P90 RSK-2 , 1997, Oncogene.
[6] E. Lees,et al. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1 , 1997, Molecular and cellular biology.
[7] K. Flaherty,et al. Elucidating distinct roles for NF1 in melanomagenesis. , 2013, Cancer discovery.
[8] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[9] Nils Blüthgen,et al. Strong negative feedback from Erk to Raf confers robustness to MAPK signalling , 2011, Molecular systems biology.
[10] O. Abdel-Wahab,et al. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. , 2015, Cancer cell.
[11] L. Wennogle,et al. Novel C‐Raf phosphorylation sites: serine 296 and 301 participate in Raf regulation , 2005, FEBS letters.
[12] Kam Y. J. Zhang,et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.
[13] Jodi Gureasko,et al. Membrane-dependent signal integration by the Ras activator Son of sevenless , 2008, Nature Structural &Molecular Biology.
[14] A. Borczuk,et al. Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. , 2010, Carcinogenesis.
[15] Jing Jiang,et al. ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling. , 2008, Cellular signalling.
[16] D. Woods,et al. Senescence of human fibroblasts induced by oncogenic Raf. , 1998, Genes & development.
[17] U. Rapp,et al. Isotype-specific functions of Raf kinases. , 1999, Experimental cell research.
[18] M. Kohno,et al. ERK pathway positively regulates the expression of Sprouty genes. , 2001, Biochemical and biophysical research communications.
[19] S. Yagel,et al. Expression and regulation of Sprouty-2 in the granulosa-lutein cells of the corpus luteum. , 2005, Molecular human reproduction.
[20] S. Nelson,et al. Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance , 2012, Nature Communications.
[21] Jurgen Müller,et al. Compartmentalization of the MAPK scaffold protein KSR1 modulates synaptic plasticity in hippocampal neurons , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[22] C. Price,et al. Fibroblast growth factor‐2 regulation of sprouty and NR4A genes in bovine ovarian granulosa cells , 2011, Journal of cellular physiology.
[23] Damien Kee,et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.
[24] J. Qin,et al. Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase. , 2005, Molecular biology of the cell.
[25] R. Seger,et al. The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions , 2006, Growth factors.
[26] D. Morrison,et al. Integrating signals from RTKs to ERK/MAPK , 2007, Oncogene.
[27] Todd R. Golub,et al. BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.
[28] D. Morrison,et al. Assay of Raf-1 activity. , 2002, Methods in enzymology.
[29] P. Shaw,et al. PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway , 2002, Oncogene.
[30] D. Fell,et al. Differential feedback regulation of the MAPK cascade underlies the quantitative differences in EGF and NGF signalling in PC12 cells , 2000, FEBS letters.
[31] P. Bastiaens,et al. Growth factor-induced MAPK network topology shapes Erk response determining PC-12 cell fate , 2007, Nature Cell Biology.
[32] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.
[33] Victoria Sanz-Moreno,et al. Ras Subcellular Localization Defines Extracellular Signal-Regulated Kinase 1 and 2 Substrate Specificity through Distinct Utilization of Scaffold Proteins , 2008, Molecular and Cellular Biology.
[34] A. Ribas,et al. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. , 2011, Cancer research.
[35] Henry C. Chang,et al. KSR, a novel protein kinase required for RAS signal transduction , 1995, Cell.
[36] David B Solit,et al. Resistance to MEK Inhibitors: Should We Co-Target Upstream? , 2011, Science Signaling.
[37] C. Sander,et al. V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway , 2009, Proceedings of the National Academy of Sciences.
[38] O. Chaika,et al. Phosphorylation of the kinase suppressor of ras by associated kinases. , 1999, Biochemistry.
[39] D. Schadendorf,et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] A. Yoshimura,et al. Mammalian Sprouty4 Suppresses Ras-Independent ERK Activation by Binding to Raf1 , 2003, Cell cycle.
[41] Kun-Liang Guan,et al. Mechanisms of regulating the Raf kinase family. , 2003, Cellular signalling.
[42] D. Morrison,et al. C-TAK1 regulates Ras signaling by phosphorylating the MAPK scaffold, KSR1. , 2001, Molecular cell.
[43] P. Serup,et al. Fgf9 signalling stimulates Spred and Sprouty expression in embryonic mouse pancreas mesenchyme. , 2011, Gene expression patterns : GEP.
[44] W. Fantl,et al. Regulation of the MAP kinase pathway by mammalian Ksr through direct interaction with MEK and ERK , 1998, Current Biology.
[45] E. Nishida,et al. Negative feedback loop in T‐cell activation through MAPK‐catalyzed threonine phosphorylation of LAT , 2004, The EMBO journal.
[46] Y. Yazaki,et al. Feedback regulation of mitogen-activated protein kinase kinase kinase activity of c-Raf-1 by insulin and phorbol ester stimulation. , 1994, The Journal of biological chemistry.
[47] G. Ladds,et al. Feedback activation of neurofibromin terminates growth factor-induced Ras activation , 2016, Cell Communication and Signaling.
[48] M. Shibuya,et al. Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1 , 2003, Nature Cell Biology.
[49] R. Dickinson,et al. Both Nuclear-Cytoplasmic Shuttling of the Dual Specificity Phosphatase MKP-3 and Its Ability to Anchor MAP Kinase in the Cytoplasm Are Mediated by a Conserved Nuclear Export Signal* , 2004, Journal of Biological Chemistry.
[50] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[51] D. Morrison,et al. Functional analysis of C‐TAK1 substrate binding and identification of PKP2 as a new C‐TAK1 substrate , 2003, The EMBO journal.
[52] J. Downward,et al. Murine Ksr interacts with MEK and inhibits Ras-induced transformation , 1998, Current Biology.
[53] I. Lax,et al. The docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors. , 2002, Molecular cell.
[54] Philip R. Cohen,et al. PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo(*) , 1995, The Journal of Biological Chemistry.
[55] D. Sacks,et al. Protein scaffolds in MAP kinase signalling. , 2009, Cellular signalling.
[56] J. Olefsky,et al. Negative Feedback Regulation and Desensitization of Insulin- and Epidermal Growth Factor-stimulated p21ras Activation (*) , 1995, The Journal of Biological Chemistry.
[57] O. Carugo,et al. A Mek1–Mek2 heterodimer determines the strength and duration of the Erk signal , 2009, Nature Structural &Molecular Biology.
[58] William Pao,et al. Genetic predictors of MEK dependence in non-small cell lung cancer. , 2008, Cancer research.
[59] Kazuhiro Aoki,et al. Multiple Decisive Phosphorylation Sites for the Negative Feedback Regulation of SOS1 via ERK* , 2010, The Journal of Biological Chemistry.
[60] M. Reth,et al. Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf , 2003, Oncogene.
[61] J. Parsons,et al. Mitogen-Activated Protein Kinase Feedback Phosphorylation Regulates MEK1 Complex Formation and Activation during Cellular Adhesion , 2004, Molecular and Cellular Biology.
[62] Ultan McDermott,et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. , 2008, Cancer research.
[63] P. Mischel,et al. Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway , 2011, PloS one.
[64] Michael A. Davies,et al. Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents , 2012, Clinical Cancer Research.
[65] P. Gibbs,et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] S. Keyse,et al. Dual-specificity MAP kinase phosphatases (MKPs) , 2013, The FEBS journal.
[67] K. Takishima,et al. Epidermal growth factor (EGF) receptor T669 peptide kinase from 3T3-L1 cells is an EGF-stimulated "MAP" kinase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[68] N. Hacohen,et al. sprouty Encodes a Novel Antagonist of FGF Signaling that Patterns Apical Branching of the Drosophila Airways , 1998, Cell.
[69] P. Cohen,et al. Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. , 1992, The Biochemical journal.
[70] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[71] A. Brunet,et al. Growth factor‐stimulated MAP kinase induces rapid retrophosphorylation and inhibition of MAP kinase kinase (MEK1) , 1994, FEBS letters.
[72] T. Tan,et al. DUSPs, to MAP kinases and beyond , 2012, Cell & Bioscience.
[73] D. Bar-Sagi,et al. Identification of the mitogen-activated protein kinase phosphorylation sites on human Sos1 that regulate interaction with Grb2 , 1996, Molecular and cellular biology.
[74] J. Sweatt,et al. Kinase Suppressor of Ras1 Compartmentalizes Hippocampal Signal Transduction and Subserves Synaptic Plasticity and Memory Formation , 2006, Neuron.
[75] Weiguo Zhang,et al. Regulation of lymphocyte development and activation by the LAT family of adapter proteins , 2009, Immunological reviews.
[76] G. Rubin,et al. Identification of Constitutive and Ras-Inducible Phosphorylation Sites of KSR: Implications for 14-3-3 Binding, Mitogen-Activated Protein Kinase Binding, and KSR Overexpression , 1999, Molecular and Cellular Biology.
[77] Robert E. Lewis,et al. The Molecular Scaffold KSR1 Regulates the Proliferative and Oncogenic Potential of Cells , 2004, Molecular and Cellular Biology.
[78] N. Rosen,et al. Tumor adaptation and resistance to RAF inhibitors , 2013, Nature Medicine.
[79] P. Edwards,et al. Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells , 2011, Science Signaling.
[80] J. Fletcher,et al. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. , 1999, Seminars in cancer biology.
[81] D. Morrison,et al. Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling , 2009, Molecular and Cellular Biology.
[82] H. Sakurai,et al. Inverse correlation between Thr‐669 and constitutive tyrosine phosphorylation in the asymmetric epidermal growth factor receptor dimer conformation , 2013, Cancer science.
[83] D. Bar-Sagi,et al. A Lipid-Anchored Grb2-Binding Protein That Links FGF-Receptor Activation to the Ras/MAPK Signaling Pathway , 1997, Cell.
[84] Ming Zhou,et al. Regulation of Raf-1 by direct feedback phosphorylation. , 2005, Molecular cell.
[85] E. Nishida,et al. Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway , 2002, Nature Cell Biology.
[86] D. Bar-Sagi,et al. Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer. , 2013, Surgery.
[87] S. Keyse,et al. Specific Inactivation and Nuclear Anchoring of Extracellular Signal-Regulated Kinase 2 by the Inducible Dual-Specificity Protein Phosphatase DUSP5 , 2005, Molecular and Cellular Biology.
[88] M. Benezra,et al. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. , 2008, The Journal of clinical endocrinology and metabolism.
[89] Muffy Calder,et al. The Mammalian MAPK/ERK Pathway Exhibits Properties of a Negative Feedback Amplifier , 2010, Science Signaling.
[90] D. Barford,et al. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. , 2005, Molecular cell.
[91] C. Robert,et al. RAF inhibition and induction of cutaneous squamous cell carcinoma , 2011, Current opinion in oncology.
[92] R. Davis,et al. Isolation and characterization of two growth factor-stimulated protein kinases that phosphorylate the epidermal growth factor receptor at threonine 669. , 1991, The Journal of biological chemistry.
[93] M. Therrien,et al. Regulation of RAF protein kinases in ERK signalling , 2015, Nature Reviews Molecular Cell Biology.
[94] R. Huganir,et al. MAPK cascade signalling and synaptic plasticity , 2004, Nature Reviews Neuroscience.
[95] Matthew Freeman,et al. Sprouty, an Intracellular Inhibitor of Ras Signaling , 1999, Cell.
[96] R. Bernards,et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma , 2014, Nature.
[97] R. Weiss,et al. MEK inhibition augments Raf activity, but has variable effects on mitogenesis, in vascular smooth muscle cells. , 1998, American journal of physiology. Cell physiology.
[98] N. Papalopulu,et al. Characterisation of a new regulator of BDNF signalling, Sprouty3, involved in axonal morphogenesis in vivo , 2010, Development.
[99] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[100] Wendell A Lim,et al. Scaffolds: interaction platforms for cellular signalling circuits. , 2009, Trends in cell biology.
[101] R. Nadeau,et al. Sprouty Genes Are Expressed in Osteoblasts and Inhibit Fibroblast Growth Factor-Mediated Osteoblast Responses , 2006, Calcified Tissue International.
[102] The developing story of Sprouty and cancer , 2014, Cancer and Metastasis Reviews.
[103] A. Ullrich,et al. EGFR and FGFR Signaling through FRS2 Is Subject to Negative Feedback Control by ERK1/2 , 2003, Biological chemistry.
[104] Christopher J. Staples,et al. Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter , 2008, The Biochemical journal.
[105] Min Han,et al. The C. elegans ksr-1 gene encodes a novel raf-related kinase involved in Ras-mediated signal transduction , 1995, Cell.
[106] N. Hacohen,et al. Sprouty: a common antagonist of FGF and EGF signaling pathways in Drosophila. , 1999, Development.
[107] D. Polsky,et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. , 2003, Cancer research.
[108] Marcus C. Ravnan,et al. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. , 2012, Clinical therapeutics.
[109] J. Otlewski,et al. ERK-Mediated Phosphorylation of Fibroblast Growth Factor Receptor 1 on Ser777 Inhibits Signaling , 2013, Science Signaling.
[110] B. Taylor,et al. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. , 2014, Cancer research.
[111] Xiwen Ma,et al. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. , 2015, Cancer cell.
[112] D. Schadendorf,et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. , 2013, Cancer discovery.
[113] S. Estrem,et al. Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma* , 2012, The Journal of Biological Chemistry.
[114] Giulio Superti‐Furga,et al. Serine and tyrosine phosphorylations cooperate in Raf‐1, but not B‐Raf activation , 1999, The EMBO journal.
[115] L. Fattore,et al. Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies , 2013, Journal of Translational Medicine.
[116] J. Reis-Filho,et al. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.
[117] H. Horvitz,et al. The ksr-1 gene encodes a novel protein kinase involved in Ras-mediated signaling in C. elegans , 1995, Cell.
[118] Deborah K. Morrison,et al. Signaling dynamics of the KSR1 scaffold complex , 2009, Proceedings of the National Academy of Sciences.
[119] J. Parsons,et al. PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation , 2003, The Journal of cell biology.
[120] S. Chandarlapaty,et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. , 2012, Cancer cell.
[121] R. Bernards,et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.
[122] M. Berger,et al. Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients , 2015, Clinical Cancer Research.
[123] S. Keyse,et al. Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. , 2000, Current opinion in cell biology.
[124] J. Licht,et al. Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. , 2006, Trends in cell biology.
[125] N. Hynes,et al. Negative Modulation of Membrane Localization of the Raf-1 Protein Kinase by Hyperphosphorylation* , 1997, The Journal of Biological Chemistry.
[126] W. Kolch,et al. Regulation and Role of Raf-1/B-Raf Heterodimerization , 2006, Molecular and Cellular Biology.
[127] Carlotta Costa,et al. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. , 2012, Cancer research.
[128] G. Guy,et al. Sprouty proteins: modified modulators, matchmakers or missing links? , 2009, The Journal of endocrinology.
[129] Chao Zhang,et al. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.
[130] Dirk Schadendorf,et al. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. , 2014, European journal of cancer.
[131] D. Morrison,et al. Identification of B-KSR1, a Novel Brain-Specific Isoform of KSR1 That Functions in Neuronal Signaling , 2000, Molecular and Cellular Biology.
[132] P. Dent,et al. Mitogen-activated protein kinase kinase 1 (MKK1) is negatively regulated by threonine phosphorylation , 1994, Molecular and cellular biology.
[133] G. Guy,et al. Sprouty2 Inhibits the Ras/MAP Kinase Pathway by Inhibiting the Activation of Raf* , 2002, The Journal of Biological Chemistry.